Tpl2 enzyme may be target for treating autoimmune diseases

May 22, 2015 by Molly Berg, University of Georgia
Nicole Acuff, left, studies whether Tpl2, a proinflammatory enzyme known as tumor locus progression 2, contributed to colitis caused by self-reactive T cells. Her research is guided by Wendy Watford, right, an assistant professor in the department of infectious diseases. Credit: Robert Newcomb/UGA

New research at the University of Georgia has found that the presence of Tpl2—an enzyme that regulates inflammation—controls the activation of T cells during colitis, an autoimmune disease that occurs when the inner lining of the colon is inflamed.

Autoimmune diseases, like colitis, are estimated to affect 5 to 8 percent of the population. Side effects of colitis can include abdominal pain, and diarrhea. Since there is no cure for colitis, most patients use medications to treat their symptoms. Figuring out the cause of colitis and how to cure it has challenged researchers for years.

Multiple cell types contribute to colitis development, including T cells. In this study, Nicole Acuff, a fourth-year Ph.D. student in the UGA College of Veterinary Medicine, led the research designed to see whether Tpl2, a proinflammatory enzyme known as tumor locus progression 2, contributed to colitis caused by self-reactive T cells.

Under the guidance of Wendy Watford, an assistant professor in the department of infectious diseases, Acuff examined the role of Tpl2 in the activation of T cells during development of the disease. The study was published recently in PLOS One.

"We specifically wanted to know how Tpl2 influences Th1 and Th17 cell development," Acuff said.

"Although these two types of T cells are important for fighting off different types of infections, their activation can go awry and lead to diverse autoimmune diseases, including colitis, rheumatoid arthritis and multiple sclerosis," Watford said.

Acuff found that when Tpl2-deficient T cells were administered to T cell-deficient mice, they were equally likely to become Th17 cells but significantly less likely to become Th1 cells. These findings suggest that Tpl2 regulates the type of inflammatory response that develops and could be targeted to treat specific types of autoimmunity. In addition, Tpl2 deficiency promotes production of anti-inflammatory proteins that antagonize Th1 and Th17 responses.

Since the research studied Tpl2's effect on mice, Acuff said that future tests are needed to better understand Tpl2 and how it could treat in humans. Follow-up studies should also examine the effects of Tpl2 on other caused by activated T .

Explore further: Researchers discover new method to reduce disease-causing inflammation

More information: "Tumor Progression Locus 2 Differentially Regulates IFNγ and IL-17 Production by Effector CD4+ T Cells in a T Cell Transfer Model of Colitis." PLoS ONE 10(3): e0119885. DOI: 10.1371/journal.pone.0119885

Related Stories

Researchers discover new method to reduce disease-causing inflammation

June 16, 2014
Researchers at the University of Georgia report in the Journal of Biological Chemistry that an enzyme known as Tumor Progression Locus 2, or Tpl2, plays a key role in directing and regulating several important components ...

Inflammatory immune cells can flip the genetic script

April 30, 2015
A type of immune cell that promotes inflammation during the immune response, TH17, can convert into another type of cell that reduces inflammation, Yale researchers have found. The finding, published April 29 in Nature, points ...

Multiple sclerosis: Scientists ID cause of movement, balance problems

May 19, 2015
New research into the causes of the excessive inflammation that drives multiple sclerosis has identified a faulty "brake" within immune cells, a brake that should be controlling the inflammation. This points to a potential ...

Protein identified that serves as a 'brake' on inflammation

April 21, 2015
Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis (MS), colitis and other autoimmune disorders. St. Jude Children's ...

Scientists discover potential new treatment for multiple sclerosis

April 27, 2015
Scientists from the Gladstone Institutes have discovered a way to prevent the development of multiple sclerosis (MS) in mice. Using a drug that blocks the production of a certain type of immune cell linked to inflammation ...

Recommended for you

Composition of complex sugars in breast milk may prevent future food allergies

June 12, 2018
The unique composition of a mother's breastmilk may help to reduce food sensitization in her infant, report researchers at the University of California San Diego School of Medicine with colleagues in Canada.

Drug may quell deadly immune response when trauma spills the contents of our cells' powerhouses

June 11, 2018
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.

Immune system does not recover despite cured hepatitis C infection

June 11, 2018
Changes to the immune system remain many years after a hepatitis C infection heals, a new study by researchers at Karolinska Institutet, Sweden, and Hannover Medical School, Germany, shows. The findings, presented in Nature ...

Food allergies connected to children with autism spectrum disorder

June 8, 2018
A new study from the University of Iowa finds that children with autism spectrum disorder (ASD) are more than twice as likely to suffer from a food allergy than children who do not have ASD.

A 'super' receptor that helps kill HIV infected cells

June 8, 2018
While treatments for HIV mean that the disease is no longer largely fatal, the world still lacks a true therapy that can eradicate the virus across a globally—and genetically different—population.

Antibody blocks inflammation, protects mice from hardened arteries and liver disease

June 6, 2018
Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.